Shares of Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) saw an uptick in trading volume on Friday . 2,670,297 shares traded hands during mid-day trading, an increase of 4% from the previous session's volume of 2,573,080 shares.The stock last traded at $26.77 and had previously closed at $26.52.
Analyst Ratings Changes
Several research firms have recently issued reports on RPRX. StockNews.com upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday. The Goldman Sachs Group raised their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a "buy" rating in a research note on Wednesday, August 14th. Finally, Citigroup reduced their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, October 25th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Royalty Pharma currently has an average rating of "Moderate Buy" and a consensus price target of $41.67.
Get Our Latest Stock Report on Royalty Pharma
Royalty Pharma Stock Down 1.2 %
The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78. The firm has a market cap of $15.55 billion, a PE ratio of 13.58, a P/E/G ratio of 3.92 and a beta of 0.47. The business's 50-day simple moving average is $27.78 and its 200 day simple moving average is $27.53.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.01. The business had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a net margin of 50.53% and a return on equity of 24.87%. During the same quarter last year, the firm posted $0.85 EPS. As a group, equities research analysts expect that Royalty Pharma plc will post 4.05 earnings per share for the current year.
Royalty Pharma Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date is Friday, November 15th. Royalty Pharma's payout ratio is currently 43.52%.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Inspire Investing LLC boosted its stake in Royalty Pharma by 175.1% in the 1st quarter. Inspire Investing LLC now owns 43,524 shares of the biopharmaceutical company's stock worth $1,322,000 after purchasing an additional 27,701 shares in the last quarter. Swedbank AB lifted its stake in Royalty Pharma by 30.6% during the 2nd quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company's stock valued at $285,151,000 after acquiring an additional 2,533,570 shares during the period. Canada Pension Plan Investment Board increased its holdings in shares of Royalty Pharma by 5.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 923,639 shares of the biopharmaceutical company's stock valued at $28,051,000 after purchasing an additional 45,839 shares in the last quarter. Tidal Investments LLC increased its holdings in shares of Royalty Pharma by 28.2% during the 1st quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company's stock valued at $2,740,000 after purchasing an additional 19,834 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Royalty Pharma by 24.5% during the 1st quarter. Russell Investments Group Ltd. now owns 402,143 shares of the biopharmaceutical company's stock valued at $12,224,000 after purchasing an additional 79,176 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.
About Royalty Pharma
(
Get Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Stories
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
